- IsoRay Takes Liberties With Lung Cancer Study Results to Prop Up Stock Price
- Shadow Work: How Businesses Are Turning Us All Into Unpaid Laborers
- Boomers' Biggest Retirement Regret? They Didn't Work Longer
- Carnival CEO Aims to Bust the Biggest Myths About the Cruise Industry
- The 10 Poorest States in America
Positive results from the new Bristol/Abbvie drug elotuzumab were featured in a media preview Wednesday ahead of the American Society of Clinical Oncology (ASCO) annual meeting.
The American Society of Clinical Oncology has provided public access to 5,000 cancer drug trial research abstracts ahead of its big annual meeting. These will be some highlights for investors.
A group of outside experts convened by the U.S. Food and Drug Administration is meeting Tuesday to review a new combination therapy for cystic fibrosis developed by Vertex Pharmaceuticals.
The odds are now high that NewLink's HyperAcute pancreas vaccine will prove to be a failure once a final survival analysis is conducted later this year or in early 2016.
MannKind's conference call on Friday morning didn't go well. Management admitted Afrezza's launch is slower than expected. Cash burn and debt remains problems which need to be addressed soon.
Investors see Alexion's willingness to write a huge check for Synageva as a tacit acknowledgment that Soliris' long-term future might be more at risk than the company lets on.
The cash and stock deal values Synageva at $230 per share, based on Alexion's average closing price for the past nine days.
The hike in Enbrel's list price pushed through by Amgen illustrates again how drug companies profit by raising the cost of their older medicines to offset falling prescription volume.
The wait goes on for NewLink Genetics to disclose the second interim analysis from the ongoing phase III study of its pancreatic cancer vaccine.
Biotech columnist Adam Feuerstein answers readers' questions about health care.